دورية أكاديمية
أعرض في EDS

Thrombocytopenia in myelodysplastic syndromes and myelofibrosis.

التفاصيل البيبلوغرافية
العنوان: Thrombocytopenia in myelodysplastic syndromes and myelofibrosis.
المؤلفون: Boruchov AM; Saint Francis Regional Cancer Center, University of Connecticut School of Medicine, Hartford, CT 06105, USA. aborucho@stfranciscare.org
المصدر: Seminars in hematology [Semin Hematol] 2009 Jan; Vol. 46 (1 Suppl 2), pp. S37-43.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0404514 Publication Model: Print Cited Medium: Print ISSN: 0037-1963 (Print) Linking ISSN: 00371963 NLM ISO Abbreviation: Semin Hematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia Pa : W.B. Saunders
Original Publication: New York.
مواضيع طبية MeSH: Myelodysplastic Syndromes/*complications , Primary Myelofibrosis/*complications , Thrombocytopenia/*blood , Thrombocytopenia/*etiology , Thrombocytopenia/*therapy, Humans ; Leukemia, Myeloid, Acute/blood ; Leukemia, Myeloid, Acute/therapy ; Myelodysplastic Syndromes/blood ; Myelodysplastic Syndromes/therapy ; Primary Myelofibrosis/blood ; Primary Myelofibrosis/therapy
مستخلص: Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by ineffective hematopoeisis and an increased risk of transforming to acute myelogenous leukemia (AML). Determining the molecular basis of the disease has been hampered by its heterogeneity. Thrombocytopenia is often a manifestation of MDS and needs to be monitored and treated accordingly. Treating the underlying disorder with a variety of differentiation and immunosuppressive agents alleviates the problem in a small percentage of patients but more often complicates the issue. Several treatments used for primary immune thrombocytopenic purpura (ITP) have been tried in MDS patients, though with only modest success rates. Preliminary studies suggest that the use of a thrombopoietic growth factor may afford substantial increases in platelet levels without excessive deleterious side effects. Primary myelofibrosis (MF) is a chronic myeloproliferative disorder associated with hepatosplenomegaly and refractory cytopenias. Immunomodulatory agents have shown promise in treating the anemia associated with this MF. However, there are currently no standard therapies to treat the thrombocytopenia that is often found in patients with this disease.
Number of References: 85
تواريخ الأحداث: Date Created: 20090228 Date Completed: 20090630 Latest Revision: 20090227
رمز التحديث: 20221213
DOI: 10.1053/j.seminhematol.2008.12.001
PMID: 19245933
قاعدة البيانات: MEDLINE
الوصف
تدمد:0037-1963
DOI:10.1053/j.seminhematol.2008.12.001